Canada Pension Plan Investment Board Has $8.52 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Canada Pension Plan Investment Board lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 77.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 178,200 shares of the biopharmaceutical company’s stock after buying an additional 78,000 shares during the period. Canada Pension Plan Investment Board owned about 0.14% of Halozyme Therapeutics worth $8,520,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Stifel Financial Corp boosted its position in Halozyme Therapeutics by 126.3% during the 3rd quarter. Stifel Financial Corp now owns 17,121 shares of the biopharmaceutical company’s stock worth $980,000 after buying an additional 9,555 shares during the period. MML Investors Services LLC lifted its holdings in shares of Halozyme Therapeutics by 80.7% during the third quarter. MML Investors Services LLC now owns 9,779 shares of the biopharmaceutical company’s stock worth $560,000 after purchasing an additional 4,366 shares during the period. M&T Bank Corp grew its stake in shares of Halozyme Therapeutics by 0.5% in the third quarter. M&T Bank Corp now owns 111,239 shares of the biopharmaceutical company’s stock worth $6,367,000 after purchasing an additional 561 shares during the last quarter. Virtu Financial LLC acquired a new stake in Halozyme Therapeutics in the third quarter valued at $434,000. Finally, World Investment Advisors LLC bought a new position in Halozyme Therapeutics during the 3rd quarter worth $3,293,000. 97.79% of the stock is currently owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the sale, the senior vice president now owns 185,453 shares of the company’s stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,200 shares of company stock valued at $1,286,568. 2.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HALO. Benchmark reissued a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. JPMorgan Chase & Co. boosted their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research report on Monday. Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $62.89.

Halozyme Therapeutics Trading Down 2.6 %

NASDAQ:HALO opened at $57.29 on Tuesday. The firm has a fifty day simple moving average of $60.44 and a two-hundred day simple moving average of $54.97. Halozyme Therapeutics, Inc. has a 12 month low of $37.97 and a 12 month high of $66.00. The stock has a market capitalization of $7.08 billion, a price-to-earnings ratio of 16.70, a PEG ratio of 0.42 and a beta of 1.32. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.